Register entry
Intra-Cellular Therapies, Inc
- Registered sites
- 0
- Drug products
- 3
- Live patents
- 56
- Countries
- 0
- Base
- Unknown
Sites
Facilities
0No registered facilities
This company holds drug listings or approvals but operates no registered establishment of its own, which is normal for an NDA holder that outsources manufacturing.
Exclusivity
Patents
56Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| CAPLYTA | LUMATEPERONE TOSYLATE | Mar 2028 |
| CAPLYTA | LUMATEPERONE TOSYLATE | Mar 2029 |
| CAPLYTA | LUMATEPERONE TOSYLATE | May 2029 |
| CAPLYTA | LUMATEPERONE TOSYLATE | Dec 2029 |
| CAPLYTA | LUMATEPERONE TOSYLATE | Aug 2033 |
| CAPLYTA | LUMATEPERONE TOSYLATE | Dec 2034 |
| CAPLYTA | LUMATEPERONE TOSYLATE | Mar 2039 |
| CAPLYTA | LUMATEPERONE TOSYLATE | Aug 2039 |
| CAPLYTA | LUMATEPERONE TOSYLATE | Oct 2039 |
| CAPLYTA | LUMATEPERONE TOSYLATE | Jul 2040 |
| CAPLYTA | LUMATEPERONE TOSYLATE | Dec 2040 |
Catalogue
Marketed products
3Showing 3 of 3.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| CAPLYTA | lumateperone | CAPSULE | NDA |
| CAPLYTA | lumateperone | CAPSULE | NDA |
| CAPLYTA | lumateperone | CAPSULE | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.